HC Wainwright reaffirmed their buy rating on shares of Revance Therapeutics (NASDAQ:RVNC – Free Report) in a research report report published on Wednesday, Benzinga reports. The firm currently has a $41.00 target price on the biopharmaceutical company’s stock. Several other equities analysts have also commented on RVNC. Needham & Company LLC lowered their price objective […]
Revance Therapeutics, Inc. (NASDAQ:RVNC – Free Report) – Investment analysts at William Blair reduced their Q3 2023 EPS estimates for shares of Revance Therapeutics in a research report issued to clients and investors on Wednesday, September 20th. William Blair analyst T. Lugo now forecasts that the biopharmaceutical company will earn ($1.43) per share for the […]
Baldwin Brothers LLC MA grew its holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC – Free Report) by 300.0% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 2,000 shares of the biopharmaceutical company’s stock after acquiring an additional 1,500 shares during the quarter. Baldwin Brothers LLC […]
Revance Therapeutics (NASDAQ:RVNC) Reaches New 12-Month Low at $17.89 theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
StockNews.com initiated coverage on shares of Revance Therapeutics (NASDAQ:RVNC – Free Report) in a report published on Thursday. The firm issued a hold rating on the biopharmaceutical company’s stock. Several other brokerages also recently issued reports on RVNC. Morgan Stanley reduced their price target on shares of Revance Therapeutics from $26.00 to $25.00 and set […]